Max Nisen, Columnist

Biotech Deals Will Bounce Back in 2017

Despite uncertainties, M&A fundamentals are improving.

January 3, 2017 at 2:12 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Biotech could really use the clean slate of a New Year. The Nasdaq Biotech Index collapsed 28 percent in the opening weeks of 2016 and never fully recovered, ending the year down about 22 percent.

One of the culprits has been a slowdown in big-time M&A -- particularly damaging for a sector that needs deal speculation to boost the share prices of companies years away from actually marketing a drug.